BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28557060)

  • 21. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
    Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
    Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.
    Han B; Tjulandin S; Hagiwara K; Normanno N; Wulandari L; Laktionov K; Hudoyo A; He Y; Zhang YP; Wang MZ; Liu CY; Ratcliffe M; McCormack R; Reck M
    Lung Cancer; 2017 Nov; 113():37-44. PubMed ID: 29110846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.
    Soo RA; Kubo A; Ando M; Kawaguchi T; Ahn MJ; Ou SI
    Clin Lung Cancer; 2017 Sep; 18(5):535-542. PubMed ID: 28433570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
    Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
    J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
    Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
    Lee B; Lee T; Lee SH; Choi YL; Han J
    Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
    Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
    Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
    Guérin A; Sasane M; Zhang J; Macalalad AR; Galebach P; Jarvis J; Kageleiry A; Culver K; Wu EQ; Wakelee H
    Cancer Epidemiol; 2015 Jun; 39(3):307-12. PubMed ID: 25914136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations.
    Kim TJ; Lee CT; Jheon SH; Park JS; Chung JH
    Ann Thorac Surg; 2016 Feb; 101(2):473-80. PubMed ID: 26454747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
    Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
    J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
    He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
    Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.